Related Experiment Video
Updated: Jul 19, 2025
Purification and Aggregation of the Amyloid Precursor Protein Intracellular Domain
Published on: August 28, 2012
APPI-Derived Cyclic Peptide Enhances Aβ42 Aggregation and Reduces Aβ42-Mediated Membrane Destabilization and
Shiran Lacham-Hartman1, Reut Moshe1, Shani Ben-Zichri2
1Avram and Stella Goldstein-Goren Department of Biotechnology Engineering and the National Institute of Biotechnology in the Negev, Ben-Gurion University of the Negev, P.O. Box 653, Beer-Sheva 84105, Israel.
Abstract:
An amyloid precursor protein inhibitor (APPI) and amyloid beta 42 (Aβ42) are both subdomains of the human transmembrane amyloid precursor protein (APP). In the brains of patients with Alzheimer's disease (AD), Aβ42 oligomerizes into aggregates of various sizes, with intermediate, low-molecular-weight Aβ42 oligomers currently being held to be the species responsible for the most neurotoxic effects associated with the disease. Strategies to ameliorate the toxicity of these intermediate Aβ42 oligomeric species include the use of short, Aβ42-interacting peptides that either inhibit the formation of the Aβ42 oligomeric species or promote their conversion to high-molecular-weight aggregates. We therefore designed such an Aβ42-interacting peptide that is based on the β-hairpin amino acid sequence of the APPI, which exhibits high similarity to the β-sheet-like aggregation site of Aβ42. Upon tight binding of this 20-mer cyclic peptide to Aβ42 (in a 1:1 molar ratio), the formation of Aβ42 aggregates was enhanced, and consequently, Aβ42-mediated cell toxicity was ameliorated. We showed that in the presence of the cyclic peptide, interactions of Aβ42 with both plasma and mitochondrial membranes and with phospholipid vesicles that mimic these membranes were inhibited. Specifically, the cyclic peptide inhibited Aβ42-mediated mitochondrial membrane depolarization and reduced Aβ42-mediated apoptosis and cell death. We suggest that the cyclic peptide modulates Aβ42 aggregation by enhancing the formation of large aggregates─as opposed to low-molecular-weight intermediates─and as such has the potential for further development as an AD therapeutic.
Insights
A novel cyclic peptide targeting amyloid beta 42 (Aβ42) enhances aggregate formation, reducing neurotoxicity in Alzheimer's disease (AD) models. This peptide shows potential for developing new AD therapeutics by modulating Aβ42 aggregation.
Area of Science:
- Neuroscience
- Biochemistry
- Drug Discovery
Background:
- Alzheimer's disease (AD) is characterized by the aggregation of amyloid beta 42 (Aβ42) oligomers, particularly intermediate species, which are highly neurotoxic.
- Current therapeutic strategies aim to inhibit Aβ42 aggregation or promote the formation of less toxic, high-molecular-weight aggregates.
- Amyloid precursor protein inhibitor (APPI) shares structural similarities with Aβ42 aggregation sites, suggesting its potential as a basis for therapeutic design.
Purpose of the Study:
- To design and evaluate a novel cyclic peptide inhibitor based on the APPI sequence for its ability to modulate Aβ42 aggregation and toxicity.
- To investigate the mechanism by which the designed peptide interacts with Aβ42 and affects its aggregation pathway.
- To assess the therapeutic potential of the peptide in ameliorating Aβ42-mediated neurotoxicity in cellular models.
Main Methods:
- A 20-mer cyclic peptide was designed based on the APPI β-hairpin sequence, targeting Aβ42 aggregation sites.
- The peptide's interaction with Aβ42 was studied, focusing on its effect on aggregate formation and Aβ42-mediated cell toxicity.
- Inhibition of Aβ42 interactions with cellular membranes (plasma and mitochondrial) and phospholipid vesicles was assessed.
- Mitochondrial membrane potential, apoptosis, and cell death were measured in the presence of the peptide.
Main Results:
- The cyclic peptide effectively bound to Aβ42 in a 1:1 molar ratio, enhancing the formation of Aβ42 aggregates.
- This enhancement of aggregate formation led to a significant amelioration of Aβ42-mediated cell toxicity.
- The peptide inhibited Aβ42 interactions with plasma and mitochondrial membranes, preventing mitochondrial depolarization, apoptosis, and cell death.
Conclusions:
- The designed cyclic peptide effectively modulates Aβ42 aggregation by promoting the formation of large aggregates over toxic intermediate species.
- The peptide demonstrates significant neuroprotective effects by inhibiting Aβ42-membrane interactions and downstream cellular damage.
- This APPI-based cyclic peptide holds promise as a potential therapeutic agent for Alzheimer's disease.
